Some roundup plaintiffs seek to delay preliminary approval of proposed USD 7.25bln Bayer (BAYN GY) settlement

Some roundup plaintiffs seek to delay preliminary approval of proposed USD 7.25bln Bayer (BAYN GY) settlement.

The request from some plaintiffs to delay the preliminary approval of Bayer's substantial settlement could introduce uncertainty around the company’s legal liabilities and financial outlook. This might lead to volatility in Bayer's shares and could also impact related sectors, particularly pharmaceuticals and equities more broadly. Traders should watch for reactions in both the stock's price and potential shifts in market sentiment related to the broader litigation climate.